Bev Incledon

1.1k total citations · 1 hit paper
32 papers, 867 citations indexed

About

Bev Incledon is a scholar working on Psychiatry and Mental health, Developmental and Educational Psychology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Bev Incledon has authored 32 papers receiving a total of 867 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Psychiatry and Mental health, 7 papers in Developmental and Educational Psychology and 5 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Bev Incledon's work include Attention Deficit Hyperactivity Disorder (28 papers), Bipolar Disorder and Treatment (9 papers) and Children's Physical and Motor Development (6 papers). Bev Incledon is often cited by papers focused on Attention Deficit Hyperactivity Disorder (28 papers), Bipolar Disorder and Treatment (9 papers) and Children's Physical and Motor Development (6 papers). Bev Incledon collaborates with scholars based in United States, Cayman Islands and Canada. Bev Incledon's co-authors include Russell P. Grant, Pratibha Sarkar, Markus Walles, Janusz Pawliszyn, Heather Lord, Christopher M. Yip, Michael R. DeFelippis, Floyd R. Sallee, Ann Childress and Timothy E. Wilens and has published in prestigious journals such as Analytical Chemistry, PEDIATRICS and Biophysical Journal.

In The Last Decade

Bev Incledon

32 papers receiving 830 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Optimization of protein precipitation based upon effectiveness of protein removal and ionization effect in liquid chromatography–tandem mass spectrometry

2003 546 citations Pratibha Sarkar, Bev Incledon et al. Journal of Chromatography B profile →

Peers

Countries citing papers authored by Bev Incledon

Since Specialization

Citations

This map shows the geographic impact of Bev Incledon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bev Incledon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bev Incledon more than expected).

Fields of papers citing papers by Bev Incledon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bev Incledon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bev Incledon. The network helps show where Bev Incledon may publish in the future.

Co-authorship network of co-authors of Bev Incledon

This figure shows the co-authorship network connecting the top 25 collaborators of Bev Incledon. A scholar is included among the top collaborators of Bev Incledon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bev Incledon. Bev Incledon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A convolution‐based in vitro‐in vivo correlation model for methylphenidate hydrochloride delayed‐release and extended‐release capsule 2023 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), Bev Incledon, Jogarao Gobburu, Roberto Goméni	2
2	Adverse Events During Dosing of Delayed-release/Extended-release Methylphenidate: Learnings From the Open-label Phase of a Registration Trial and a Real-world Postmarketing Surveillance Program 2023 ·Clinical Therapeutics ·Martin A. Katzman, (unknown), (unknown), (unknown), Bev Incledon	1
3	Effect of Delayed-Release and Extended-Release Methylphenidate on Caregiver Strain and Validation of Psychometric Properties of the Caregiver Strain Questionnaire: Results from a Phase 3 Trial in Children with Attention-Deficit/Hyperactivity Disorder 2021 ·Journal of Child and Adolescent Psychopharmacology ·Frank A. López, Stephen V. Faraone, Jeffrey H. Newcorn, Helen Doll, (unknown), Hannah B Lewis, (unknown), (unknown), Floyd R. Sallee, Bev Incledon, (unknown)	5
4	Symptomatic and Functional Response and Remission From the Open-Label Treatment-Optimization Phase of a Study With DR/ER-MPH in Children With ADHD 2021 ·The Journal of Clinical Psychiatry ·Ann Childress, Andrew J. Cutler, (unknown), (unknown), Lewis Warrington, Floyd R. Sallee, Bev Incledon	5
5	Clinically Meaningful Improvements in Early Morning and Late Afternoon/Evening Functional Impairment in Children with ADHD Treated with Delayed-Release and Extended-Release Methylphenidate 2021 ·Journal of Attention Disorders ·Timothy E. Wilens, Stephen V. Faraone, Paul Hammerness, Steven R. Pliszka, (unknown), (unknown), Floyd R. Sallee, Bev Incledon, Jeffrey H. Newcorn	7
6	IMPROVEMENTS IN EMOTIONAL LABILITY WITH DELAYED-RELEASE AND EXTENDED-RELEASE METHYLPHENIDATE TREATMENT IN CHILDREN WITH ADHD 2021 ·Journal of the American Academy of Child & Adolescent Psychiatry ·Valerie Arnold, Frank A. López, Ann Childress, (unknown), Ryan A. Gregg, Floyd R. Sallee, Bev Incledon	2
7	A Post Hoc Comparison of Prior ADHD Medication Dose and Optimized Delayed-release and Extended-release Methylphenidate Dose in a Pivotal Phase III Trial 2020 ·Clinical Therapeutics ·Ann Childress, (unknown), (unknown), (unknown), Bev Incledon	5
8	Model-Based Approach for Establishing the Predicted Clinical Response of a Delayed-Release and Extended-Release Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder 2020 ·Journal of Clinical Psychopharmacology ·Roberto Goméni, Marina Komolova, Bev Incledon, Stephen V. Faraone	10
9	Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate: Evaluation of Dose Proportionality, Food Effect, Multiple-Dose Modeling, and Comparative Bioavailability with Immediate-Release Methylphenidate in Healthy Adults 2019 ·Journal of Child and Adolescent Psychopharmacology ·Tao Liu, Jogarao Gobburu, (unknown), (unknown), (unknown), Floyd R. Sallee, Bev Incledon	15
10	A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings 2019 ·Journal of Child and Adolescent Psychopharmacology ·Ann Childress, Andrew J. Cutler, (unknown), (unknown), John M. Turnbow, Matthew Brams, (unknown), Bev Incledon, Floyd R. Sallee, Sharon B. Wigal	21
11	Functional Impairment in Youth With ADHD 2019 ·The Journal of Clinical Psychiatry ·Stephen V. Faraone, (unknown), Marina Komolova, (unknown), Bev Incledon, Timothy E. Wilens	9
12	6.51 ACHIEVEMENT AND MAINTENANCE OF NORMALIZED LEVELS OF EARLY MORNING AND LATE AFTERNOON/EVENING FUNCTIONAL IMPAIRMENT WITH DELAYED-RELEASE AND EXTENDED-RELEASE METHYLPHENIDATE (DR/ER-MPH) IN CHILDREN WITH ADHD: POST HOC ANALYSES OF BEFORE-SCHOOL FUNCTIONING 2019 ·Journal of the American Academy of Child & Adolescent Psychiatry ·Stephen V. Faraone, Timothy E. Wilens, Ann Childress, Andrew J. Cutler, (unknown), (unknown), Floyd R. Sallee, Bev Incledon, Sharon B. Wigal	3
13	2.23 Efficacy and Safety of Delayed-Release and Extended-Release Methylphenidate (DR/ER-MPH) in Children With ADHD: Results From a Pivotal Phase 3 Classroom Trial 2018 ·Journal of the American Academy of Child & Adolescent Psychiatry ·Ann Childress, Andrew J. Cutler, (unknown), (unknown), Bev Incledon, (unknown)	2
14	Efficacy and Safety of HLD200, a Novel Delayed-Release and Extended-Release Methylphenidate Formulation, in Children With Attention-Deficit/Hyperactivity Disorder: Results From a Pivotal Phase 3 Trial 2018 ·PEDIATRICS ·Steven R. Pliszka, Timothy E. Wilens, (unknown), Valerie Arnold, (unknown), Andrew J. Cutler, Frank A. López, (unknown), Floyd R. Sallee, Bev Incledon, Jeffrey H. Newcorn	2
15	128 Effect of DR/ER-MPH on Early Morning and Late Afternoon/Evening Functioning in Children With ADHD: Analysis of PREMB-R Items From a Phase 3 Trial 2018 ·CNS Spectrums ·Steven R. Pliszka, Valerie Arnold, (unknown), (unknown), Bev Incledon, (unknown), Timothy E. Wilens, Jeffrey H. Newcorn	2
16	Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder 2017 ·Journal of Child and Adolescent Psychopharmacology ·Ann Childress, (unknown), Jogarao Gobburu, (unknown), (unknown), Bev Incledon	22
17	Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder 2017 ·Journal of Child and Adolescent Psychopharmacology ·Steven R. Pliszka, Timothy E. Wilens, (unknown), Valerie Arnold, (unknown), Andrew J. Cutler, Frank A. López, (unknown), Floyd R. Sallee, Bev Incledon, Jeffrey H. Newcorn, (unknown)	26
18	Amyloid Fibrils of Glucagon Characterized by High-Resolution Atomic Force Microscopy 2006 ·Biophysical Journal ·(unknown), Bev Incledon, Christopher M. Yip, Michael R. DeFelippis	60
19	Optimization of protein precipitation based upon effectiveness of protein removal and ionization effect in liquid chromatography–tandem mass spectrometry breakdown → 2003 ·Journal of Chromatography B ·(unknown), Pratibha Sarkar, Bev Incledon, (unknown), Russell P. Grant	546
20	Development and Evaluation of a Solid-Phase Microextraction Probe for in Vivo Pharmacokinetic Studies 2003 ·Analytical Chemistry ·Heather Lord, Russell P. Grant, Markus Walles, Bev Incledon, (unknown), Janusz Pawliszyn	93

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact